Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,442 stopped studies mapped to Adenocarcinoma and descendants · 92% state a reason
Over the 1,442 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and… | Phase 1 | terminated | Sep 25, 2017 | Hoffmann-La Roche | Portfolio prioritization | Sponsor / business decision |
| NCT04399824 | Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer | N/A | withdrawn | May 22, 2020 | Jonsson Comprehensive Cancer Center | Study did not open | Other (stated, no rule matched) |
| NCT04142554 | Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer(LCCC1820) | Phase 1 | withdrawn | Oct 29, 2019 | UNC Lineberger Comprehensive Cancer Center | Funding withdrawn from funding source. | Funding |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT04315155 | Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated…(BENEFIT) | Phase 1 | withdrawn | Mar 19, 2020 | University of Utah | study abandoned for funding issues | Funding |
| NCT01673386 | A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With…(TAURUS) | Phase 2 | terminated | Aug 28, 2012 | AVEO Pharmaceuticals, Inc. | Sponsor | Other (stated, no rule matched) |
| NCT01745367 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic…(BATON-BC) | Phase 2 | terminated | Dec 10, 2012 | AVEO Pharmaceuticals, Inc. | low enrollment | Enrollment / accrual |
| NCT02595918 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | Phase 1 | terminated | Nov 4, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04270461 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | Phase 1 | withdrawn | Feb 17, 2020 | Jiujiang University Affiliated Hospital | Study is withdrawn because of administrative reasons | Other (stated, no rule matched) |
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal… | Phase 1 / Phase 2 | terminated | Mar 7, 2013 | Tracon Pharmaceuticals Inc. | The study did not meet endpoint. | Other (stated, no rule matched) |
| NCT02558205 | Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry | — | withdrawn | Sep 23, 2015 | Rush University Medical Center | unable to rectuir | Other (stated, no rule matched) |
| NCT02095210 | HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025 | Phase 1 | terminated | Mar 24, 2014 | Dorte Nielsen | slow recruitment | Enrollment / accrual |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With…(TRAP) | Phase 1 | terminated | Jan 8, 2014 | Polaris Group | not stated | Not stated |
| NCT01697293 | PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients… | Phase 1 / Phase 2 | terminated | Oct 2, 2012 | Prescient Therapeutics, Ltd. | criteria for continuing enrollment in Phase 2 portion was not met | Enrollment / accrual |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | Phase 2 | terminated | Jun 27, 2018 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT04044326 | The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant… | N/A | withdrawn | Aug 5, 2019 | National Taiwan University Hospital | Machine cannot provide | Other (stated, no rule matched) |
| NCT04546802 | HepATocellular Cancer Hcv Therapy Study(HATCHeT) | Phase 3 | withdrawn | Sep 14, 2020 | Bayside Health | Recruitment will be too difficult due to available PBS funded treatment and recent Australian… | Enrollment / accrual |
| NCT03203837 | Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | — | terminated | Jun 29, 2017 | Northwestern University | Funding Discontinued due to low accrual rate | Enrollment / accrual |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or… | Phase 2 | withdrawn | Sep 27, 2019 | M.D. Anderson Cancer Center | No Participants Registered | Other (stated, no rule matched) |
| NCT01367275 | Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated… | Phase 2 | terminated | Jun 7, 2011 | M.D. Anderson Cancer Center | Sponsor closed study | Other (stated, no rule matched) |
| NCT03644511 | Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent…(SORAGO-HCC) | — | terminated | Aug 23, 2018 | Bayer | The interest of potential centers is very limited. | Other (stated, no rule matched) |
| NCT03172559 | Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not…(RADBRI) | N/A | withdrawn | Jun 1, 2017 | University Health Network, Toronto | Investigator decided not to pursue the study due to other competing studies. | Investigator |
| NCT03598816 | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for…(PIVOT-RCC) | Phase 2 | withdrawn | Jul 26, 2018 | Washington University School of Medicine | FDA Contingencies unresolved | Other (stated, no rule matched) |
| NCT04260360 | Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma | Phase 1 | withdrawn | Feb 7, 2020 | NanOlogy, LLC | Not initiated | Other (stated, no rule matched) |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Phase 1 | terminated | Apr 27, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT01859689 | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer | Phase 2 | withdrawn | May 22, 2013 | Jonsson Comprehensive Cancer Center | no participants enrolled | Enrollment / accrual |
| NCT02597894 | Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing… | N/A | withdrawn | Nov 5, 2015 | Jonsson Comprehensive Cancer Center | P. I. left the Institution. Study never opened | Other (stated, no rule matched) |
| NCT02168062 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and… | Phase 2 | terminated | Jun 20, 2014 | University of California, San Francisco | Funding | Funding |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell… | Phase 1 | terminated | Aug 8, 2014 | Merck Sharp & Dohme LLC | Terminated early due to low enrollment | Enrollment / accrual |
| NCT02892734 | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative… | Phase 2 | terminated | Sep 8, 2016 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT02170389 | Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer | N/A | terminated | Jun 23, 2014 | Roswell Park Cancer Institute | sponsor having financial difficulties | Funding |
| NCT03890198 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and… | Early Phase 1 | terminated | Mar 26, 2019 | First Affiliated Hospital Xi'an Jiaotong University | the Preliminary data, progress of this study and the adjustment of the pipeline and strategy . | Sponsor / business decision |
| NCT04395118 | STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs(STOP-HCC) | N/A | withdrawn | May 20, 2020 | University of Texas Southwestern Medical Center | Study will not be conducted as a RCT due to limited project timeline. | Other (stated, no rule matched) |
| NCT00953446 | Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of… | N/A | terminated | Aug 6, 2009 | Beth Israel Deaconess Medical Center | not stated | Not stated |
| NCT02089334 | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal… | Phase 1 / Phase 2 | terminated | Mar 17, 2014 | Rexahn Pharmaceuticals, Inc. | not stated | Not stated |
| NCT03300609 | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After… | Phase 3 | terminated | Oct 3, 2017 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT04149444 | A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer(TACTIC) | Phase 2 | withdrawn | Nov 4, 2019 | AHS Cancer Control Alberta | Sponsor withdrew support | Other (stated, no rule matched) |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid… | Phase 1 | terminated | Nov 17, 2017 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT02989870 | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | Phase 1 | withdrawn | Dec 12, 2016 | H. Lee Moffitt Cancer Center and Research Institute | No Interest. Investigator was unable to enroll any participants on study. | Investigator |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell… | Phase 1 | terminated | Jul 20, 2016 | Celldex Therapeutics | Development of CDX-014 discontinued | Other (stated, no rule matched) |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by… | Phase 1 / Phase 2 | terminated | Mar 29, 2018 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT04093648 | T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor… | Phase 1 | withdrawn | Sep 18, 2019 | Baylor College of Medicine | The key elements of this study were incorporated into another study. | Other (stated, no rule matched) |
| NCT01486134 | Major RF Ablations of Hepatomas Under MR Thermometry Monitoring(ARMTICH) | N/A | terminated | Dec 6, 2011 | Assistance Publique - Hôpitaux de Paris | For technical reasons | Other (stated, no rule matched) |
| NCT01409811 | Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated… | N/A | terminated | Aug 4, 2011 | City of Hope Medical Center | Study closed after it became too difficult to interest patients in participating. | Other (stated, no rule matched) |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | Phase 1 / Phase 2 | withdrawn | Apr 25, 2019 | HealthPartners Institute | funding issues | Funding |
| NCT02013778 | Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC | Phase 1 / Phase 2 | terminated | Dec 17, 2013 | Abramson Cancer Center at Penn Medicine | Lack of enrollment | Enrollment / accrual |
| NCT01060345 | A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ | Phase 2 | terminated | Feb 2, 2010 | University of Chicago | Drug no longer available | Other (stated, no rule matched) |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal… | Phase 1 / Phase 2 | withdrawn | Nov 14, 2018 | University of Southern California | PI left | Investigator |
| NCT03748927 | Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma | — | withdrawn | Nov 21, 2018 | National Cancer Institute (NCI) | slow/insufficient accrual | Enrollment / accrual |
| NCT03990974 | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC…(HCC) | Phase 3 | suspended | Jun 19, 2019 | Sun Yat-sen University | There were difficulties in implementation | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Nov 6, 2020source: clinicaltrials